222 related articles for article (PubMed ID: 1360020)
1. Prolactin bioassay and hyperprolactinemia.
Peabody CA; Schultz PN; Warner MD; Worsley IG; Friesen HG; Samaan NA
J Endocrinol Invest; 1992; 15(7):497-9. PubMed ID: 1360020
[TBL] [Abstract][Full Text] [Related]
2. CV 205-502--effectiveness, tolerability, and safety over 24-month study.
Shoham Z; Homburg R; Jacobs HS
Fertil Steril; 1991 Mar; 55(3):501-6. PubMed ID: 1672113
[TBL] [Abstract][Full Text] [Related]
3. Changes in the prolactin serum isoforms secreted by a pituitary adenoma associated with therapy.
Morán C; Tena G; Fonseca ME; Ochoa R; Bermúdez JA; Zárate A
Arch Med Res; 1994; 25(1):1-3. PubMed ID: 8019107
[TBL] [Abstract][Full Text] [Related]
4. Characterization of big, big prolactin in patients with hyperprolactinaemia.
Leite V; Cosby H; Sobrinho LG; Fresnoza MA; Santos MA; Friesen HG
Clin Endocrinol (Oxf); 1992 Oct; 37(4):365-72. PubMed ID: 1483294
[TBL] [Abstract][Full Text] [Related]
5. Amenorrhea, galactorrhea, and hyperprolactinemia.
Magyar DM
J Am Osteopath Assoc; 1985 Jun; 85(6):375-80. PubMed ID: 3905728
[No Abstract] [Full Text] [Related]
6. Hyperprolactinemia. Its relation to galactorrhea, amenorrhea, pituitary tumor and its management.
Ge QS; Xu L; Wang HL; Gu CX; Lin SQ; Xu YD; Yu KM; Xie YZ; Shi YF; Zang X
Chin Med J (Engl); 1985 Aug; 98(8):543-50. PubMed ID: 3937678
[No Abstract] [Full Text] [Related]
7. Diagnostic evaluation of hyperprolactinemia.
Biller BM
J Reprod Med; 1999 Dec; 44(12 Suppl):1095-9. PubMed ID: 10649817
[TBL] [Abstract][Full Text] [Related]
8. Clinical presentation of hyperprolactinemia.
Luciano AA
J Reprod Med; 1999 Dec; 44(12 Suppl):1085-90. PubMed ID: 10649815
[TBL] [Abstract][Full Text] [Related]
9. Two-step development of a pituitary adenoma: from hyperprolactinemic syndrome to Cushing's disease.
Gheri RG; Boddi W; Ammannati F; Olivotto J; Nozzoli C; Franchi A; Bordi L; Luisi ML; Mennonna P
J Endocrinol Invest; 1997 Apr; 20(4):240-4. PubMed ID: 9211134
[TBL] [Abstract][Full Text] [Related]
10. Headache, hyperprolactinemia, and prolactinomas.
Strebel PM; Zacur HA; Gold EB
Obstet Gynecol; 1986 Aug; 68(2):195-9. PubMed ID: 3737035
[TBL] [Abstract][Full Text] [Related]
11. Galactorrhea-amenorrhea and hyperprolactinemia associated with pituitary tumors of growth-hormone- and adrenocorticotropic-hormone-secreting cells. A report of two cases.
Haney AF; McCarty KS; Hammond CB
J Reprod Med; 1984 Dec; 29(12):883-7. PubMed ID: 6097688
[TBL] [Abstract][Full Text] [Related]
12. Serum prolactin and growth hormone determined by radioimmunoassay and a two-site immunoradiometric assay: comparison with the Nb2 cell bioassay.
Rose DP; Berke B; Cohen LA
Horm Metab Res; 1988 Jan; 20(1):49-53. PubMed ID: 3371857
[TBL] [Abstract][Full Text] [Related]
13. [The combined stimulation test sulpiride-TRH in the investigation of prolactin secretion].
Miras-Mirakian P; Claustrat F; Dechaud H; Pugeat M
J Gynecol Obstet Biol Reprod (Paris); 1992; 21(4):419-23. PubMed ID: 1624729
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of prolactin bioassay in euprolactinemic reproductive disorders.
Ataya KM; Subramanian MG; Moghissi KS; Magyar DM; Hayes MF; Lawson DM; Gala RR
Fertil Steril; 1988 Jan; 49(1):71-5. PubMed ID: 3335274
[TBL] [Abstract][Full Text] [Related]
15. CV 205-502 treatment of macroprolactinomas.
Crottaz B; Uske A; Reymond MJ; Rey F; Siegel RA; Brownell J; Gomez F
J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study.
van der Heijden PF; Lappöhn RE; Corbey RS; de Goeij WB; Brownell J; Rolland R
Fertil Steril; 1989 Oct; 52(4):574-9. PubMed ID: 2806597
[TBL] [Abstract][Full Text] [Related]
17. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
Giusti M; Porcella E; Carraro A; Cuttica M; Valenti S; Giordano G
J Endocrinol Invest; 1994 Jan; 17(1):51-7. PubMed ID: 7911813
[TBL] [Abstract][Full Text] [Related]
18. [Primary hypothyroidism presenting with amenorrhea, galactorrhea, hyperprolactinemia and enlarged pituitary].
Tadmor OP; Barr I; Diamant YZ
Harefuah; 1992 Jan; 122(2):76-8. PubMed ID: 1572562
[TBL] [Abstract][Full Text] [Related]
19. [Heterogeneity of immunoreactive prolactin in hyperprolactinemia of various origin].
Bulatov AA; Makarovskaia EE; Dzeranova LK; Smirnova NB; Chernogolov VA; Marova EI; Mel'nichenko GA; Dedov II
Probl Endokrinol (Mosk); 1992; 38(6):13-6. PubMed ID: 1302839
[TBL] [Abstract][Full Text] [Related]
20. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502.
Rasmussen C; Brownell J; Bergh T
Acta Endocrinol (Copenh); 1991 Aug; 125(2):170-6. PubMed ID: 1680264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
